Parkinsonism: differential age-trend in Helicobacter pylori antibody
Article first published online: 24 DEC 2001
Alimentary Pharmacology & Therapeutics
Volume 14, Issue 9, pages 1199–1205, September 2000
How to Cite
Dobbs, Charlett, Dobbs, Weller and Peterson (2000), Parkinsonism: differential age-trend in Helicobacter pylori antibody. Alimentary Pharmacology & Therapeutics, 14: 1199–1205. doi: 10.1046/j.1365-2036.2000.00815.x
- Issue published online: 24 DEC 2001
- Article first published online: 24 DEC 2001
Parkinsonism is associated with prodromal peptic ulceration. Dopamine antagonists provoke experimental ulcer, dopaminergic agents protect, and might inhibit growth of Helicobacter pylori.
To describe the relationship between H. pylori serology and parkinsonism.
Serum H. pylori anti-urease-IgG antibody was measured in 105 people with (idiopathic) parkinsonism, 210 without, from same locality. None had received specific eradication therapy.
Controls showed a birth-cohort effect: antibody titre rose from 30 to 90 years (P < 0.001). Parkinsonism obliterated this (disease status · age interaction, P < 0.05), the differential age trend not being attributable to social class. Those with diagnosed parkinsonism were more likely to be seropositive (odds ratio 2.04 (95% CI: 1.04, 4.22) P < 0.04) before 72.5 years. Overall, titre fell (P=0.01) by 5 (1, 9)% per unit increase in a global, 30-point rating (median 14 (interquartile range 10.5, 17)) of disease severity. No individual category of anti-parkinsonian medication (92% taking) had a differential lowering effect.
Higher prevalence of seropositivity in parkinsonism, before 8th decade, may be due to host susceptibility/reaction, or, conversely, infection with particular H. pylori strain(s) lowering dopaminergic status. Absence of a birth cohort effect in parkinsonism, despite similar social class representation, may be consequent on eradication, spontaneous (gastric atrophy) or by anti-parkinsonian medication.